These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 9577110)

  • 1. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip & total knee arthroplasty: a cost comparison.
    Garcia-Zozaya I
    J Ky Med Assoc; 1998 Apr; 96(4):143-8. PubMed ID: 9577110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery.
    Menzin J; Colditz GA; Regan MM; Richner RE; Oster G
    Arch Intern Med; 1995 Apr; 155(7):757-64. PubMed ID: 7695464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM
    Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery.
    Hawkins DW; Langley PC; Krueger KP
    Clin Ther; 1998; 20(1):182-95. PubMed ID: 9522114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective.
    Hull RD; Raskob GE; Pineo GF; Feldstein W; Rosenbloom D; Gafni A; Green D; Feinglass J; Trowbridge AA; Elliott CG
    Arch Intern Med; 1997 Feb; 157(3):298-303. PubMed ID: 9040296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.
    Duran A; Sengupta N; Diamantopoulos A; Forster F; Kwong L; Lees M
    J Med Econ; 2011; 14(6):824-34. PubMed ID: 22023098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Venous thromboembolism prophylaxis after total hip arthroplasty].
    Kučera T; Malý R; Urban K; Sponer P
    Acta Chir Orthop Traumatol Cech; 2011; 78(2):101-5. PubMed ID: 21575551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
    Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
    Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
    Olsen J; Gundgaard J; Borris LC
    Ugeskr Laeger; 2005 May; 167(21):2273-9. PubMed ID: 15962854
    [No Abstract]   [Full Text] [Related]  

  • 17. Preventing DVT following total knee replacement: a review of recent clinical trials.
    Fitzgerald RH
    Orthopedics; 1995 Jul; 18 Suppl():10-1. PubMed ID: 7479418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DVT prophylaxis: better living through chemistry: affirms.
    Pellegrini VD
    Orthopedics; 2010 Sep; 33(9):642. PubMed ID: 20839678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
    Enyart JJ; Jones RJ
    Ann Pharmacother; 2005 Jun; 39(6):1002-7. PubMed ID: 15886295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States.
    Botteman MF; Caprini J; Stephens JM; Nadipelli V; Bell CF; Pashos CL; Cohen AT
    Clin Ther; 2002 Nov; 24(11):1960-86; discussion 1938. PubMed ID: 12501885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.